



**Information webinar of the  
Programme Committee for the  
specific programme  
implementing Horizon 2020 - the  
Framework  
Programme for Research and  
Innovation (2014-2020) –**

**Configuration ‘Health,  
demographic change and well-  
being’**

17 September 10.00 – 13.00

Videoconference

## Meetings with WebEx



•Make sure you are correctly identified  
(COUNTRY – full name)



•Respect confidentiality



•Please keep your microphone muted and your camera off  
during the meeting.



•How to ask questions or the floor?

Please use the Chat function.

Unmute your mic only when the chair invites you to take the floor.  
Do not use the Chat function to start discussions.



## Overview:

- Policy context, including the ERAvsCorona Action Plan
- Preliminary results of the COVID-19 R&I portfolio analysis
- Presentation of the results of actions funded in the updates of the Horizon2020SC-1 'Health, demographic change and wellbeing' Work Programme 2018-2020 to implement urgent actions of the ERAvsCorona Action Plan
- AOB: update on H2020 Green Deal Call



## ERAvsCorona Action Plan & International cooperation

- **Rapid, pragmatic, novel way of coordinating EU action at service level by Commission and Member States** to respond to EU Leaders' commitment "to do everything possible to support research, to coordinate efforts and seek synergies within European scientific and research community" (Joint Statement EU Leaders 26 March).
- **10 short-term actions, notably:** Extending clinical trials, support to innovative companies, sharing research data, EU Hackathon and a second "Call for an Expression of interest"
- **Ministers:** Supported the Action Plan during an informal videoconference on 7 April; Action Plan was made public.
- **International pledging conference starting on Monday 4 May 2020:** Aim to raise €7.5 billion in initial funding to kick-start the global cooperation (sizeable amount for R&I)



## ERAvsCorona Action Plan: 10 priority actions (1)

1. Coordination of R&I funding against the Coronavirus
2. ***Extending and supporting large EU wide clinical trials for clinical management of Coronavirus patients***
3. ***New funding for innovative and rapid health-related approaches to respond to coronavirus and deliver quick results relevant to society and a higher level of preparedness of health systems***
4. Increasing support to innovative companies
5. Creating opportunities for other funding sources to contribute to R&I actions on Coronavirus



## ERAvsCorona Action Plan: 10 priority actions (2)

6. Establish a one-stop shop for Coronavirus R&I funding
7. Establish an ad-hoc High Level R&I Task Force on the Coronavirus
8. Access to Research Infrastructures
9. Research data sharing platform
10. Pan-EU Hackathon to mobilise European innovators and civil society



## Research Action Vs Coronavirus: *other initiatives*

- A [European COVID-19 Data Platform](#) was set up to enable the rapid collection and sharing of available research data. It is the result of a joint effort by the European Commission and other entities including the European Bioinformatics Institute of the European Molecular Biology Laboratory (EMBL-EBI)
- [E-Pitching event](#) of innovative solutions to support European public & private procurers against COVID19” organised by the European Innovation Council on the 30 April.
- **On-going grants for research infrastructures** have been topped up with almost €11 million;
- A **pan-European Hackathon [EUvsVirus](#)**, was organised in April. It was the largest in the world, with 21.000 participants and 2160 solutions, out of which 120 were selected as winners.
- In May, **Matchathon [EUvsVirus](#)** event took place to match the needs with available resources and to boost the scaling up of creative solutions to coronavirus challenges.


→ for more information check [our website on Coronavirus Research and Innovation](#)

## Research Action Vs Coronavirus: *funding mobilised*

Initiative		EUR
<b>1<sup>st</sup> EoI for research &amp; innovation (March 2020)</b>	to develop diagnostics, treatments and vaccines (18 projects)	48.2 million
<b>IMI COVID fast track call</b>	for treatments and diagnostics	72 million
<b>Coalition for Epidemic Preparedness Innovations (CEPI)</b>	EUR 50 million were mobilized + EUR 50 million in the final approval process	100 million
<b>EDCTP COVID19 EoI</b>	with co-funding from France, Sweden, South Africa and UK (20 projects)	25.25 million
<b>EIC Accelerator pilot</b>	COVID-19 related proposals	165.63 million
<b>2<sup>nd</sup> EoI for research &amp; innovation (July 2020)</b>	strengthening capacity to manufacture and deploying readily available solutions, including understanding of the behavioral and socio-economic impacts (23 projects)	128.2 million
<b>InnovFin Infection Diseases Financial Facility (IDFF)</b>	Debt financing to CureVac Debt financing to BioNTech	75 million 100 million
<b>EIT Health</b>	COVID-19 Rapid Response Call and call for Digital Health solutions with a minimum TRL of 8 and direct impact on the current crisis	6 million



## Sources of H2020 grant funding dedicated directly to COVID-19 R&I via COVID-19 calls in 2020 *(first analysis – early Sept 2020)*





## Portfolio analysis of EU R&I actions to combat COVID-19

- Up till September 2020, dedicated COVID-19 H2020 calls (Health SC1 and other calls) disbursed **EUR 440.6 million** to **103 projects**:
  - development of diagnostics, treatments, vaccines, epidemiology, preparedness.
  - response to outbreaks, socioeconomics, production and digital technologies
  - infrastructures and data resources that enable this research.
- EC RTD portfolio analysis has shown 547 projects (funded by FP7 and H2020) with COVID-19 applications:
  - scientific knowledge
  - solutions in e.g. new disinfectant coatings for protective clothing, in safely transporting patients, in waste water treatment and in digital applications.




## Distribution of COVID-19 H2020 projects\* according to major needs by EU financial contribution (M euro)



\* funded through Horizon 2020 Health, demographic change and wellbeing and other H2020 funding instruments

## Distribution of COVID-19 projects according to main type of beneficiaries – by the share of EU financial contribution




\* funded through Horizon 2020 Health, demographic change and wellbeing and other H2020 funding instruments

# Top-10 participants in COVID-19 H2020 Projects - by EU financial contribution (M euro)



\* funded through Horizon 2020 Health, demographic change and wellbeing and other H2020 funding instruments


# Distribution of EU R&I funding and number of participants per EU Member State and Associated Country






## Participants from 14 third countries in projects receiving grants from COVID-19 specific calls:

Argentina, Australia, Brazil, Canada, China, Columbia, Congo, Cote d'Ivoire, Gabon, India, Korea, Nepal, South Africa and the United States.



\* funded through Horizon 2020 Health, demographic change and wellbeing and other H2020 funding instruments

## Preliminary analysis of the distribution of 547 FP7 and H2020 projects reoriented to fight the COVID-19 emergency according to major needs (number of projects per category)



## Horizon 2020 projects of dedicated COVID-19 calls deliver early results

### Exscalate4CoV

revealed using a supercomputing platform that an already registered generic drug used to treat osteoporosis, Raloxifene, could be an effective treatment for COVID-19 positive patients with mild or asymptomatic infection

### HG nCoV19

developed a new portable diagnostic system to detect viral infection that gives accurate and reliable results in 30 minutes

### Prevent-nCoV

working on a vaccine against COVID-19 shows promising results in mice. Clinical phase may already start this year.



# **Updates of the Horizon2020 SC-1 Work Programme 2018-2020 to implement urgent actions of the ERAvsCorona Action Plan:**

**information to and consultation with the Programme Committee Configuration 'Health, demographic change and well-being'**



## H2020 information and consultation process related to COVID-19 (1)

- 30 January 2020: information on the special request for an Expression of Interest H2020-SC1-PHE-CORONAVIRUS-2020 followed by updates on 31 January, 4 and 7 February
- 4 March: information about the outcome of the Expression of Interest H2020-SC1-PHE-CORONAVIRUS-2020
- 5 March: request to vote on H2020 SC1 WP2018-2020 update including Increase of 37.5 M€ for the Public Health Emergency action (Other Action 6), to respond to the ongoing Covid-19 Public Health Emergency of International Concern
- 20 March: information about new web page presenting all EC-funded coronavirus-related research



## H2020 information and consultation process related to COVID-19 (2)

- 31 March and 3 April request to vote on grants from the expression of interest H2020-SC1-2020-PHE-CORONAVIRUS
- 22 April information about planned updates to the H2020 SC1 WP2018-2020 to implement urgent actions of the ERAvsCorona Action Plan (i.e. a second call for expression of interest, direct funding to targeted clinical trials, and an increase of funding to CEPI \*)
- 7 May WebEx meeting, further information about planned updates to the H2020 SC1 WP2018-2020

\* Actions were discussed by Ministers responsible for research and innovation during an informal videoconference of the Competitiveness Council of 7 April 2020, on the basis of a number of dialogues between the Commission services and the national ministries.



## H2020 information and consultation process related to COVID-19 (3)

- 15 May: information on the special request for Expression of Interest H2020-SC1-PHE-CORONAVIRUS-2020-2
- 18 May: information about the launch of the Expression of Interest H2020-SC1-PHE-CORONAVIRUS-2020-2 and request to vote on updates to the H2020 SC1 WP2018-2020 on Public Health Emergency
- 23 June: additional information on the EU-wide COVID19 Clinical Trial network (DisCoVeR and REMAP-CAP/COVID)
- 10 August: information about the outcome of the Expression of Interest H2020-SC1-PHE-CORONAVIRUS-2020-2



## H2020 information and consultation process related to COVID-19 (4)

- 25 August: request to vote on batch 1 of 2 grants from the expression of interest H2020-IBA-SC1-CORONAVIRUS-2020-3 (EU-RESPONSE and SUPPORT-E)
- 9 September: information on the 2<sup>nd</sup> ePitching to Procurers of innovation against COVID-19, event takes place on 17 September.
- 17 September: WebEx meeting information on the results of the second expression of interest, clinical trials and other types of support activities linked to the ERAvsCorona Action Plan



# Overview of the implementation of the changes in the 2018-2020 Work Programme in response to the consequences of the COVID-19 pandemic

- Implements priority actions of the 'ERAvsCorona Action Plan and delivers the EU's commitment to Coronavirus Global Response International Pledging
- Aims to support wide scale, rapid (within 3-18 months) applications of solutions to respond quickly to immediate needs of the ongoing health emergency.



## Main changes proposed to the 2018-2020 Work Programme in response to the consequences of the COVID-19 pandemic

- Additional contribution of € 50 M to the € 50 M already foreseen in the Work programme, bringing the total to €100 million to **Coalition for Epidemic Preparedness Innovations (CEPI)** to deliver the EU's commitment to the 'Coronavirus Global Response International Pledging Event' (launched on 4 May 2020).
- Implementing Action 2 of the ERAvsCorona Action Plan to financially support the **inclusion of additional research sites in ongoing large multi-centric EU-wide COVID-19 clinical trials** and further **enhancing data sharing**



## Towards an EU-wide clinical trials network (Action 2 in ERAvsCOVID Action Plan)


**Aim:** enable the **collaboration and coordination** between Member States and research sites, to support the implementation of **large-scale, multi-centric COVID-19 clinical trials across Europe**

- Generation of *robust evidence* to support regulatory decisions & to inform public health policy
- Enrol a *sufficient number of patients/volunteers* and harmonise data collection
- Necessary *agility* to rapidly react to regional developments of the pandemic and *integrate new research findings*
- Support *overcoming* political, ethical, administrative, regulatory and logistical (PEARL) *hurdles* for rapid implementation or adaptation of clinical trials

# Our vision

## Network based on Adaptive Platform Trials (APT)

649600



\* PEARL barriers: Political, ethical, administrative, regulatory and logistical barriers



## Additional funding for EU wide COVID-19 clinical trials

- **EU-RESPONSE:** Adaptive platform trial to investigate several treatment options for COVID-19 hospitalized patients (non ICU).
- **SUPPORT-E:** to coordinate efforts by gathering Member States initiatives to collect **convalescent plasma for treatment** purposes.
- **RECOVER:** Remap Cap adaptive platform trial **for ICU patients**

Now on to vaccine trials....



## Additional funding

- Further **development of the COVID19 data sharing platform**: VEO (*raw and annotated SARS-CoV-2 genomic data*) & RECODID (*clinical-epidemiological COVID-19 cohort data and the link to high-dimensional data*)
- Reinforcement of ongoing COVID-19 **research to address important public health questions** : EpiPose project (*extension of behavioural studies in different countries*) & I-MOVE-COVID-19 (*expand (hospital based) surveillance*)
- Reinforcement of **international coordination** - GLOPID R secretariat (*leadership and communication*) & SONAR Global (*extension and exploitation of social science network*)



## Results of the Second 'Call for an Expression of Interest': budget € 128 million (Action 3 of the ERAvsCOVID-19 Action Plan)

- Implements the priorities outlined in action 3 of the ERAvsCorona Action Plan, in 4 areas.
- Uses similar process as 1st 'Expression of Interest' of January 2020 as the EU response to the COVID-19 pandemic, which led to the funding of 18 projects in March 2020.

## Expression of Interest SC1-PHE-CORONAVIRUS-2020

Topic	Action type	Budget € million	Budget/ proposal € million	Proposals submitted
SC1-PHE-CORONAVIRUS-2020-2A - Repurposing of manufacturing for vital medical supplies and equipment	IA	23	5-6	36
SC1-PHE-CORONAVIRUS-2020-2B - Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)	IA	56	2-5	221
SC1-PHE-CORONAVIRUS-2020-2C - Behavioural, social and economic impacts of the outbreak responses	RIA	20	4-10	162
SC1-PHE-CORONAVIRUS-2020-2D - Pan-European COVID-19 cohorts	RIA	20	15-20	21
SC1-PHE-CORONAVIRUS-2020-2E - Networking of existing EU and international cohorts of relevance to COVID-19	CSA	3	2-3	14



## Expression of Interest SC1-PHE-CORONAVIRUS-2020 Applicants in evaluated proposals

Sub-topic	EU	Associated Countries	Third countries	UK	Total
SC1-PHE-CORONAVIRUS-2020-2A	298	37	3	16	354
SC1-PHE-CORONAVIRUS-2020-2B	1534	138	29	98	1799
SC1-PHE-CORONAVIRUS-2020-2C	1576	169	80	106	1931
SC1-PHE-CORONAVIRUS-2020-2D	270	33	16	18	337
SC1-PHE-CORONAVIRUS-2020-2E	135	11	37	12	195



## SC1-PHE-CORONAVIRUS-2020-2A - Repurposing of manufacturing for vital medical supplies and equipment

- New processes for the repurposing, adaptation and ramp-up of production lines to strengthen Europe's ability to adjust quickly to new and urgent production needs.
- Ability to deliver demonstrators of industrial response capability for requalification or release of production lines. Open Innovation Testbeds, laboratories, technology infrastructures and other collaborative solutions may be relevant.



## SC1-PHE-CORONAVIRUS-2020-2A - Repurposing of manufacturing for vital medical supplies and equipment

- Proposals submitted: **36** (5 ineligible inadmissible)
- Experts evaluating: **21**
- Indicative budget: **€ 23 million**
- Allocated budget: **€ 22,130,459.94**

<i>Proposals evaluated</i>	<i>Above threshold</i>	<i>Main list</i>	<i>Reserve list</i>
<b>31</b>	<b>11</b>	<b>4</b>	<b>1</b>

- General remarks: The proposals were in general of good quality. A wide variety of medical supplies were addressed (masks, screens, respirators, etc.), including the enhanced resilience for the linked supply chains. Fast and flexible repurposing of manufacturing lines was well considered in the top ranked proposals. Some lower scoring proposals focussed too much on product development rather than repurposing.

## SC1-PHE-CORONAVIRUS-2020-2A - Repurposing of manufacturing for vital medical supplies and equipment

### imPURE

repurposing and digitally transforming plastic processing industrial lines for the production of critical medical consumables (PPE, ventilator accessories, fingertip pulse oximeter)

### CO-VERSATILE

re-orientation and repurposing of production capacities of vital medical supplies and equipment (PPE, respirators)

### Eur3ka

rapid manufacturing repurposing for an increased and sudden demand of medical supplies and equipment (PPE, clinical care equipment)

### RESERVIST

establish 'reservist cells' be activated within 48hrs to switch to manufacturing medical products and services that are spiking in demand (PEE, ventilators)



## SC1-PHE-CORONAVIRUS-2020-2B - Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)

- a) fast, cost-effective and easily deployable sampling, screening, diagnostic and prognostic systems, to detect the presence of the pathogen related parameters especially in an early stage of infection;
- b) environmental surveillance (sewage, air, etc.) systems and data analytics as a sentinel for viral (re)emergence and spread in communities;
- c) low cost sensors, smart wearable devices and robotics/AI for telemedicine, telepresence and continuous remote monitoring of patient parameters;
- d) protection of healthcare practitioners and the general public - disinfection and social distancing in environments such as healthcare, public spaces and buildings;
- e) innovative data-driven services and tools combining data assets from various relevant privately held and/or publicly available sources, for diagnostics, prevention, treatment, or rehabilitation.



## SC1-PHE-CORONAVIRUS-2020-2B - Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)

- Proposals submitted: **221** (10 ineligible or inadmissible)
- Experts evaluating: **101**
- Indicative budget: **€ 56 million**
- Allocated budget: **€ 55,175,532.64**


<i>Proposals evaluated</i>	<i>Above threshold</i>	<i>Main list</i>	<i>Reserve list</i>
<b>211</b>	<b>87</b>	<b>13</b>	<b>3</b>

- General remarks:
  - Good coverage of the 5 technology areas of the topic
  - Overall a wide coverage of applicants across Europe and H2020 associated countries



European  
Commission

## SC1-PHE-CORONAVIRUS-2020-2B – Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)





## SC1-PHE-CORONAVIRUS-2020-2C - Behavioural, social and economic impacts of the outbreak responses

- To provide health authorities with guidance for further public health interventions and to support implementation of actions.
- Holistic assessments of social, economic and political impacts of the outbreak and its responses across Europe for improving industry's and society's adaptation capacity and resilience and a fast recovery of the current healthcare emergency.



## SC1-PHE-CORONAVIRUS-2020-2C - Behavioural, social and economic impacts of the outbreak responses

- Proposals submitted: **162** (10 ineligible/inadmissible)
- Experts evaluating: **66**
- Indicative budget: € **20 million**
- Allocated budget: € **28 million**

<i>Proposals evaluated</i>	<i>Above threshold</i>	<i>Main list</i>	<i>Reserve list</i>
<b>152</b>	<b>47</b>	<b>4</b>	<b>9</b>



# SC1-PHE-CORONAVIRUS-2020-2C - Behavioural, social and economic impacts of the outbreak responses

## COVINFORM

COronavirus Vulnerabilities and INFormation dynamics Research and Modelling

## PERISCOPE

Pan-European Response to the ImpactS of COVID-19 and future Pandemics and Epidemics

## Share-COVID

Non-intended health, economic and social effects of the COVID-19 epidemic control decisions: Lessons from SHARE

## RESPOND

Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic



## SC1-PHE-CORONAVIRUS-2020-2D - Pan-European COVID-19 cohorts

- Cohorts with both infected and non-infected individuals, which will provide vital information for health policies in clinical management and preventive and protective strategies, as well as assessment of impact of COVID-19 and the varying mitigating measures on health, well-being and socio-economic factors of individuals.
- Wide geographical area in Europe and other parts of the world called for, and interaction with national and/or European biobanks encouraged.



## SC1-PHE-CORONAVIRUS-2020-2D - Pan-European COVID-19 cohorts

- Proposals submitted: **21** (2 ineligible/inadmissible)
- Experts evaluating: **24**
- Indicative budget: **€ 20 million**
- Allocated budget: **€ 19.9 million**

<i><b>Proposals evaluated</b></i>	<i><b>Above threshold</b></i>	<i><b>Main list</b></i>	<i><b>Reserve list</b></i>
<b>19</b>	<b>9</b>	<b>1</b>	<b>2</b>



## SC1-PHE-CORONAVIRUS-2020-2D - Pan-European COVID-19 cohorts

### ORCHESTRA

Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic



## SC1-PHE-CORONAVIRUS-2020-2E - Networking of existing EU and international cohorts of relevance to COVID-19

- Support the international networking of existing, mainly longitudinal, cohorts in order to extract jointly agreed standardized data on COVID-19 diagnosed/serotyped and matched non-infected individuals.
- Help in the identification of key factors influencing the susceptibility to infection and clinical manifestation, to assess the optimized therapeutic and clinical management options, and to derive lessons on the health and socio-economic impacts of the pandemic. Create a cohort framework to rapidly address pandemics in the future.



## SC1-PHE-CORONAVIRUS-2020-2E - Networking of existing EU and international cohorts of relevance to COVID-19

- Proposals submitted: **14** (all eligible)
- Experts evaluating: **11**
- Indicative budget: **€ 3 million**
- Allocated budget: **€ 3 million**

<i>Proposals evaluated</i>	<i>Above threshold</i>	<i>Main list</i>	<i>Reserve list</i>
<b>14</b>	<b>4</b>	<b>1</b>	<b>1</b>



## SC1-PHE-CORONAVIRUS-2020-2E - Networking of existing EU and international cohorts of relevance to COVID-19

**unCoVer**

Unravelling Data for Rapid Evidence-Based  
Response to COVID-19



## Further information:

- **The 23 projects shortlisted for funding included participants from:**
  - countries associated to the Horizon 2020 programme (Bosnia-Herzegovina, Israel, Norway, Serbia, Switzerland and Turkey)
  - third countries (Argentina, Australia, Brazil, Columbia, Congo, Gabon, India, Korea, South Africa and the United States).
- **Open Access + data sharing:** Beneficiaries **must make available their research data**, at the latest within 30 days after it has been generated, through open access or, if agreed by the Commission, by giving access rights to those third parties that need the research data to address the public health emergency.
- **Exploitation obligations:** In the context of the public health emergency, results or resulting products/services will be available and accessible, as soon as possible and at fair conditions. This will include an obligation to license on a non-exclusive basis and at fair and reasonable conditions.



The EU Framework Programme for Research and Innovation

HORIZON 2020

# The Green Deal Call 2020



# The Green Deal Call

- directly relevant to the Green Deal objectives
- **Aim:**
  - to produce tangible results,
  - visible to the citizens,
  - in a relatively short time frame.
- To increase impact and visibility, proposed actions should be **limited in number** supporting primarily innovation and demonstration actions.
- Emphasis would be given to systemic, cross-sectoral approaches.
- Budget close to 1 billion EUR

# The Green Deal Call

The call contains 11 areas

**Eight thematic areas** reflecting the key work streams of the European Green Deal. In each area, one or more topics addresses the challenges outlined in the respective stream. Topics target specific, high-impact technological and societal innovations that can help advance the sustainable transition relatively quickly.

**Three horizontal areas** (strengthening knowledge; empowering citizens; and international cooperation) that cut across the eight thematic areas and offer a longer-term perspective in achieving the transformations set out in the European Green Deal.

# The Green Deal Call - Skeleton

## Green Deal domains

**Area 1:**  
*increasing climate ambition and Green Deal impact with cross-cutting solutions*

**Area 2:**  
*supplying clean, affordable and secure energy*

**Area 3:**  
*industry for a clean and circular economy*

**Area 4:**  
*energy and resource efficient buildings*

**Area 5:**  
*sustainable and smart mobility*

**Area 6:**  
*Farm to Fork*

**Area 7:**  
*restoring biodiversity and ecosystem services*

**Area 8:**  
*a zero-pollution ambition for a toxic-free environment*

## Horizontal topics

*strengthening our knowledge in support of the European Green Deal*

*empowering citizens for the transition towards a climate neutral, sustainable Europe*

*accelerating the clean energy transition and access in partnership with Africa and the Mediterranean*

## Area 8 topics

### **Topic1: Innovative, systemic zero-pollution solutions to protect health, environment and natural resources from persistent and mobile chemicals**

- This call topic aims at demonstrating innovative solutions to protect health, environment and natural resources from persistent and mobile chemicals, such as per- and polyfluoroalkyl substances (PFAS).
- Increasing concern as they are persistent in the environment, very mobile, toxic and can bioaccumulate. Many people exposed.
- Health effects: low infant birth weights, effects on the immune system, cancer and thyroid hormone disruption.
- Available budget: 40 M€ (Projects € 8-12 million)



## Area 8 topics

### **Topic 2: Fostering regulatory science to address chemical and pharmaceutical mixtures: from science to evidence-based policies**

- This call topic aims at applied research studies, demonstrating how regulatory science can apply new tools and methodological approaches based on the latest scientific evidence, to quantify and prevent harmful co-exposures to industrial chemicals and pharmaceuticals.
- Will include studies on effects on humans, in particular on vulnerable sub-populations, from combined (chronic) exposure to low levels of pharmaceuticals via the environment
- Available budget: € 20 million (Projects €4-6 million)

- Specific website available:  
[https://ec.europa.eu/info/research-and-innovation/strategy/european-green-deal/call\\_en](https://ec.europa.eu/info/research-and-innovation/strategy/european-green-deal/call_en)
- Info Day during R&I Days: 23 September at 16h-18h (100 people allowed per session)
- Call to be published within a week, evaluation organised by EASME in early 2021



**Thank you**



# Back-up slides



# Expression of Interest SC1-PHE-CORONAVIRUS-2020 Evaluation outcome

Sub-topic	Indicative budget € million	Proposals submitted	Ineligible or inadmissible proposals	Proposals evaluated	Experts evaluating	Proposals above threshold	Proposals retained	Budget retained proposals €	Proposals reserve list
SC1-PHE-CORONAVIRUS-2020-2A	23	36	5	31	21	11	4	22,130,459.94	1
SC1-PHE-CORONAVIRUS-2020-2B	56	221	10	211	101	87	13	55,175,532.64	3
SC1-PHE-CORONAVIRUS-2020-2C	20	162	10	152	66	47	4	28,048,612.00	9
SC1-PHE-CORONAVIRUS-2020-2D	20	21	2	19	24	9	1	19,887,643.75	2
SC1-PHE-CORONAVIRUS-2020-2E	3	14	-	14	11	4	1	2,997,440.00	1
<b>Total</b>	<b>122</b>	<b>454</b>	<b>27</b>	<b>427</b>	<b>223</b>	<b>158</b>	<b>23</b>	<b>128,239,688.33</b>	<b>17</b>